EDA and X-linked hypohidrotic ectodermal dysplasia: However, a novel therapeutic approach to XLHED based on a recombinant EDA molecule (a fusion protein consisting of the receptor-binding domain of EDA1 and the Fc domain of human IgG1) proved successful in animal models of the disease (Gaide and Schneider 2003; Hermes et al., 2014; Margolis et al., 2019), and intra-amniotic administration of this replacement protein has been shown to prevent most XLHED symptoms in human patients (Schneider et al., 2018; Körber et al., 2020).